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Reference Products and WHO International Standards/Reference Reagents have roles to play in the
development and characterization of similar biological products (SBPs). However, these roles are distinct
and non-interchangeable. The uses of these materials and their limitations are considered in this paper.
 World Health Organization 2011. All rights reserved. The World Health Organization has granted the
Publisher permission for the reproduction of this article.1. Introduction
Both reference products and WHO International standards/
reference reagents have distinct and important roles to play in the
development and characterization of similar biological products. In
this article, the intended purpose of these materials is described.2. Uses of the Reference Product
The reference product is key and fundamental in the develop-
ment of SBPs. It is the ‘comparator’ for all the comparability studies
i.e. for quality, nonclinical and clinical assessment [1e4]. It is ideally
a product that has been approved and marketed in the relevant
country or geographical area, which has a long established history
of good efﬁcacy and safety. It should be marketed at a level which
allows the purchase of a number of different batches, so that the
comparability assessment can be sufﬁciently thorough. This implies
that the most likely reference product for use as a comparator in
SBP development will be the market leader in the country where
the SBP is being developed, although this is not a requirement.
For quality assessment, the SBP should be compared directly in
the same assays (i.e. a head-to-head comparison) with the refer-
ence product using a range of biological, physico-chemical and
sometimes immunological procedures (Table 1). The choice of such
methods depends on the biosimilar under development. In some
cases, the reference product can be used directly as purchased e.g.,
from a pharmacy, but in other cases, ‘extraction’ of the drug
substance from the product is needed as the excipients used in the; fax: þ44 (0) 1707 641 053.
.uk (R. Thorpe), Meenu.
ll rights reserved. The World Healthformulation may interfere with at least some procedures used for
analysis. In such instances, it is important to avoid changes induced
in the product by the extraction method. In some situations where
this problem is likely to be encountered, it may be advantageous to
also treat the SBP with the same extraction procedure used for the
reference product to attempt to replicate the effects induced.
For the nonclinical and clinical studies, the SBP must be
compared to the reference product directly (using the head-to-
head, comparative approach). Clinical trials need to be carefully
designed to assess comparative efﬁcacy and safety.
The same reference product should be used throughout the
quality, safety and efﬁcacy comparability program during the
development of a biosimilar product. The dosage form, dose, and
route of administration of the biosimilar biological product should
be identical to those of the reference product. A product authorized
as a biosimilar product should not be used as the reference product.
3. Uses of WHO International Standards/Reference Reagents
WHO International Standards/Reference Reagents are primary
standards (sometimes referred to as ‘gold’ standards) and are
available for a wide range of substances (see Table 2). They are
produced to deﬁned standards [5] which optimize retention of
biological activity and other important characteristics as well as
ensuring stability. These reagents are established by the Expert
Committee on Biological Standardization of WHO following an
international collaborative study in which the suitability of the
preparation to serve as a standard is demonstrated (for example,
see [6]). They are intended to last for a considerable period, (usually
several decades) as replacing them is time consuming and expen-
sive and they often contain excipients which may interfere with
physico-chemical methods. Such standards are produced inOrganization has granted the Publisher permission for the reproduction of this article.
Table 1
Examples of analytical tests used for characterization of biotherapeutic medicines.
Parameter Analytical test
Primary structure Amino acid analysis, LC-ESI-MS, N/C-terminal
sequencing, peptide map, MS, RP-HPLC
Higher order structure CD spectroscopy, NMR spectroscopy,
peptide map, SE-HPLC, SDS-PAGE, bioassay,
binding assay
Size AUC, MALDI TOF MS, LC-ESI-MS, SE-HPLC,
SDS-PAGE
Charge IEC, IEF, CE
Glycosylation pattern/
sequence, glycosylation site
CE, LC-ESI-MS, MALDI TOF MS, RP-HPLC,
peptide map, HPAEC, IEC-HPLC
Heterogeneity e.g.,
Amino acid sequence/
substitution, deamidation,
oxidation, aggregation,
truncation/fragmentation
CE, Peptide map, RP-HPLC, SE-HPLC,
IEC-HPLC, SDS-PAGE, MS, IEF, AUC, DLS, CE
LC e liquid chromatography, ESI e electrospray ionization, MS e mass spectrom-
etry, CD e circular dichroism, NMR e nuclear magnetic resonance, AUC e analytical
ultracentrifugation, SE-HPLC e Size exclusion high performance liquid chromatog-
raphy, RP-HPLCe reverse phase high performance liquid chromatography, IECe Ion
exchange chromatography, IEF e Isoelectric focusing, CE e Capillary electropho-
resis, SDS-PAGE e Sodium dodecyl sulfate polyacrylamide gel electrophoresis, DLS
e dynamic light scattering, MALDI e TOF MS, matrix assisted laser desorption/
ionization time of ﬂight, HPAEC e high pH anion exchange chromatography.
Table 2
Available WHO International Standards, WHO Reference Reagents and NIBSC Reference R
NIBSC (http://www.nibsc.ac.uk/products/biological_reference_materials/product_catalo
CytoMarch11.pdf).
International Standards/Reference Reagents
Alpha-1-antitrypsin (WHO 1st International Standard)
Antithrombin, concentrate, human (WHO 3rd International Standard)
Factors II & X, concentrate, human (WHO 3rd International Standard)
Factor VII, concentrate, human (WHO 1st International Standard)
Factor VIIa, concentrate (WHO 2nd International Standard) (07/228)
Factor VIII, concentrate, human (WHO 8th International Standard)
Factor IX, concentrate, human (WHO 4th International Standard)
Factor IXa, concentrate, human (WHO 1st International Standard)
Factor XIII, plasma, human (WHO 1st International Standard)
Factor Eight Inhibitor By-passing Activity (FEIBA), concentrate (1st NIBSC Working Sta
Fibrinogen, concentrate, human (WHO 1st International Standard)
Heparin, Low Molecular Weight (WHO 2nd International Standard)
Heparin, Unfractionated, porcine (WHO 6th International Standard)
Prekallikrein activator, human (WHO 2nd International Standard)
Protein C, concentrate, human (WHO 1st International Standard)
Staphylokinase (NIBSC Reagent)
Streptodornase (WHO 2nd International Standard)
Streptokinase (WHO 3rd International Standard)
Thrombin (WHO 2nd International Standard)
Urokinase, high molecular weight (WHO 1st International Standard)
von Willebrand factor, concentrate, human (WHO 1st International Standard)
Activin A, Human, Recombinant (1st WHO International Standard)
C-Peptide of Human Insulin (1st International Reference Reagent)
Calcitonin, ASU 1e7 Eel Calcitonin Analog (Elcatonin) (1st WHO International Standar
Calcitonin, Eel (1st WHO International Standard)
Calcitonin, Human (2nd WHO International Standard)
Calcitonin, Salmon (3rd WHO International Standard)
Chorionic Gonadatrophin, beta core fragment, Human, for immunoassay (1st WHO Re
Chorionic Gonadatrophin, intact, Human, for immunoassay (1st WHO Reference Reage
Chorionic Gonadotrophin alpha subunit, Human (1st International Reference Preparat
Chorionic Gonadotrophin beta Subunit, Human (1st International Reference Preparatio
Chorionic Gonadotrophin, alpha subunit, Human (puriﬁed), for immunoassay (1st WH
Chorionic Gonadotrophin, beta subunit, Human, for immunoassay (1st WHO Referenc
Chorionic Gonadotrophin (5th WHO International Standard)
Chorionic Gonadotrophin, nicked beta subunit, Human, for immunoassay (1st WHO R
Chorionic Gonadotrophin, nicked, human, for immunoassay (1st WHO Reference Reag
Corticotrophin (ACTH), Human (NIBSC Research Reagent)
Erythropoietin, Human Recombinant (2nd WHO International Standard)
Follicle Stimulating Hormone and Luteinizing Hormone, Human Urinary, for bioa
Follicle Stimulating Hormone, Human, Recombinant for immunoassay (1st WHO Inter
Follicle Stimulating Hormone, Human, Recombinant for bioassay (1st WHO Intern
Follicle Stimulating Hormone, Pituitary (1st WHO International Standard)
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are used either to calibrate secondary standards, such European
Pharmacopoeial or USP Reference materials, or manufacturers
working standards.
Although primarily intended for the calibration, characteriza-
tion and validation of potency assays, often bioassays [7], the
substances can also be used with other assays and procedures in
some cases. Such standards are usually calibrated in units or
International Units which are often arbitrarily deﬁned and relate to
the ampoule content of the analyte. These standards are used to
calibrate bioassays either directly or for calibration of secondary or
working standards [6,7]. The use of a single primary standard
worldwide facilitates the comparability of assay results. Standards
must be included in each bioassay run and the potency of unknown
samples can be calculated by comparison of the displacement of
their doseeresponse curves from that generated using the stan-
dard. Calibration of bioassays in terms of parameters such as 50%
maximum proliferation etc. is not normally valid as this effectively
ignores the potency of the standard.
Bioassay-derived potency data must be accompanied by a valid
statement of the uncertainty associated with the measurement [7].
Statistical procedures have been devised for the calculation of the
degree of error associated with such determinations. This iseagents for Biotherapeutics. A list of WHO International Standards is available on the
gue.aspx) and WHO websites (http://www.who.int/bloodproducts/catalogue/
Code
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Table 2 (continued )
International Standards/Reference Reagents Code
Follicle Stimulating Hormone, urofollitropin, Human Urinary for bioassay (1st WHO International Standard) 92/512
Glucagon, Porcine (1st WHO International Standard) 69/194
Growth Hormone, Human, Pituitary (1st WHO International Standard) 80/505a
Inhibin A, Human, recombinant (1st WHO International Standard) 91/624
Inhibin B, Human (1st WHO Reference Reagent) 96/784
Inhibin, Porcine (1st WHO International Standard) 86/690
Insulin Like Growth Factor- I (1st WHO International Standard) 02/254
Insulin, Bovine (1st WHO International Standard) 83/511
Insulin, Human (1st WHO International Standard) 83/500a
Insulin, Human for immunoassay (1st International Reference Preparation) 66/304
Insulin, Porcine (1st WHO International Standard) 83/515
Insulin-Like Growth Factor Binding Protein-3 (NIBSC Research Reagent 93/560
Insulin-like growth factor-1 for bioassay (1st WHO International Standard) 91/554
Insulin-like growth factor-II, Human, recombinant (1st WHO Reference Reagent) 96/538
Luteinizing Hormone, Human, recombinant (1st WHO International Standard) 96/602a
Luteinizing Hormone, Human, Pituitary (2nd WHO International Standard) 80/552
Luteinizing Hormone, Pituitary, alpha subunit (1st WHO International Standard) 78/554
Luteinizing Hormone, Pituitary, beta subunit (1st WHO International Standard) 78/556
Parathyroid hormone 1-34 Recombinant, Human (1st WHO International Standard) 04/200
Parathyroid Hormone, Bovine, for bioassay (1st WHO International Standard) 82/632
Parathyroid Hormone, Human (NIBSC Research Standard) 75/549
Parathyroid Hormone, Human, for immunoassay (1st International Reference Preparation) 79/500
Parathyroid Hormone, Human, recombinant (1st WHO International Standard) 95/646a
Placental Lactogen, Human, for immunoassay (1st International Reference Preparation) 73/545
Proinsulin, Human, for immunoassay (1st International Reference Reagent) 84/611
Proinsulin, Porcine, for immunoassay (1st International Reference Reagent) 84/528
Prolactin Human, recombinant, glycosylated (1st WHO Reference Reagent) 98/580a
Prolactin, Human (3rd WHO International Standard) 84/500
Prolactin, Human, recombinant (1st WHO Reference Reagent) 97/714
Prolactin, Human, recombinant, non-glycosylated (1st WHO Reference Reagent) 98/582
Serum amyloid A protein (1st WHO International Standard) 92/680
Somatropin (2nd WHO International Standard) 98/574
Tetracosactide for bioassay (1st International Reference Preparation) 80/590
Thyroid Stimulating Antibody (1st WHO International Standard) 90/672
Thyroid Stimulating Hormone, Human, for bioassay (non-WHO Reference material) 00/504
Thyroid Stimulating Hormone, Human, for immunoassay (3rd WHO International Standard) 81/565
Thyroid Stimulating Hormone, Human recombinant (1st WHO Reference Reagent) 94/674
Thyroid Stimulating Hormone, Human, recombinant, for bioassay (1st WHO International Standard) 03/192
Basic Fibroblast Growth Factor (FGF-2) rDNA (WHO 1st International Standard) 90/712
Bone e Morphogenetic Protein-2 rDNA (WHO Reference Reagent) 93/574
Brain-derived neurotrophic factor (BDNF) rDNA (WHO Reference Reagent) 96/534
Ciliary Neurotrophic Factor rDNA (WHO Reference Reagent) 94/684
Epidermal Growth Factor rDNA (WHO 1st International Standard) 91/530
Epidermal Growth Factor (1e52) rDNA (WHO 1st International Standard) 91/550
Fms-like tyrosine Kinase-3 rDNA (WHO Reference Reagent) 96/532
Granulocyte Colony Stimulating Factor rDNA (WHO 2nd International Standard) 09/136a
Granulocyte Macrophage Colony Stimulating Factor rDNA (WHO 1st International Standard) 88/646a
Hepatocyte Growth Factor/Scatter Factor rDNA (WHO 1st International Standard) 96/564
Hepatocyte Growth Factor/Scatter Factor precursor rDNA (WHO 1st International Standard) 96/556
Interleukin-1 alpha rDNA (WHO 1st International Standard) 86/632
Interleukin-1 beta rDNA (WHO 1st International Standard) 86/680
Interleukin-1 receptor antagonist (NIBSC Reference Reagent) 92/644
Interleukin-2 Cell line derived (WHO 1st International Standard) 86/504a
Interleukin-2 rDNA (NIBSC Reference Reagent) 86/564
Interleukin-2 soluble receptor rDNA (NIBSC Reference Reagent) 97/600
Interleukin-3 rDNA (WHO 1st International Standard) 91/510
Interleukin-4 rDNA (WHO 1st International Standard) 88/656
Interleukin-5 rDNA (WHO Reference Reagent) 90/586
Interleukin-6 rDNA (WHO 1st International Standard) 89/548
Interleukin-7 rDNA (WHO Reference Reagent) 90/530
Interleukin-8 rDNA (WHO 1st International Standard) 89/520
Interleukin-9 rDNA (WHO Reference Reagent) 91/678
Interleukin-10 rDNA (WHO Reference Reagent) 93/722
Interleukin-11 rDNA (WHO Reference Reagent) 92/788a
Interleukin-12 rDNA (WHO Reference Reagent) 95/544
Interleukin-13 rDNA (WHO Reference Reagent) 94/622
Interleukin-15 rDNA (WHO Reference Reagent) 95/554
Interleukin-17 rDNA (WHO Reference Reagent) 01/420
Interleukin-18 rDNA (WHO Reference Reagent) 03/200
Interferon alpha leukocyte (WHO 1st International Standard) 94/784
Interferon alpha 1 rDNA (WHO 1st International Standard) 83/514
Interferon alpha 1/8 rDNA (WHO 1st International Standard) 95/572
Interferon alpha 2a rDNA (WHO 2nd International Standard) 95/650a
Interferon alpha 2b rDNA (WHO 2nd International Standard) 95/566a
Interferon alpha 2c rDNA (WHO 1st International Standard) 95/580
Interferon alpha n1 lymphoblastoid (WHO 2nd International Standard) 95/568
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Table 2 (continued )
International Standards/Reference Reagents Code
Interferon alpha n3 leucocyte (WHO 1st International Standard) 95/574
Interferon alpha consensus rDNA (WHO 1st International Standard) 94/786
Interferon omega rDNA (WHO 1st International Standard) 94/754
Interferon beta rDNA (WHO 3rd International Standard) 00/572a
Interferon beta Ser17 rDNA (NIBSC Reference Reagent) 00/574a
Interferon beta, Fibroblast (NIBSC Reference Reagent) 00/576
Interferon gamma rDNA (NIBSC Reference Reagent) 87/586
Interferon gamma, Human Leukocyte (British Working Standard) 82/587
Keratinocyte Growth Factor (FGF-7) rDNA (WHO Reference Reagent) 03/150
Keratinocyte Growth Factor (24e163) rDNA (WHO Reference Reagent) 03/148
Leptin rDNA (WHO 1st International Standard) 97/594
Leukemia inhibitory factor rDNA (WHO Reference Reagent) 93/562
Macrophage colony stimulating factor rDNA (WHO 1st International Standard) 89/512
Nerve Growth Factor rDNA (WHO Reference Reagent) 95/566
Neurotrophin rDNA (NIBSC Reference Reagent) 98/718
Oncostatin M rDNA (WHO Reference Reagent) 93/564
Platelet derived growth factor BB rDNA (WHO 1st International Standard) 94/728
Stem Cell Factor rDNA (WHO Reference Reagent) 91/682
Thrombopoietin rDNA (NIBSC Reference Reagent) 03/124
Transforming Growth factor beta-1 rDNA (NIBSC Reference Reagent) 89/514
Transforming Growth factor beta-2 rDNA (NIBSC Reference Reagent) 90/696
Transforming Growth factor beta-3 rDNA (NIBSC Reference Reagent) 98/608
Tumor necrosis factor-alpha rDNA (WHO 2nd International Standard) 88/786
Tumor necrosis factor-beta rDNA (WHO Reference Reagent) 87/640
Tumor-necrosis-factor related apoptosis inducing ligand rDNA (WHO Reference Reagent) 04/166
Tumor necrosis factor soluble receptor I rDNA (NIBSC Reference Reagent) 96/528
Tumor necrosis factor soluble receptor II rDNA (NIBSC Reference Reagent) 93/524
Vascular Endothelial Growth Factor 165 rDNA (WHO Reference Reagent) 02/286
a Denotes standards available for biosimilars (approved or in development).
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limits of the potency estimate. Bioassaysmust be carefully designed
to minimize and allow an assessment of the errors associated with
the derived potency value.
4. Inappropriate uses of Reference Products and WHO
International Standards/Reference Reagents
Reference products are, in effect, approved clinical products
usually obtained in the containers in which they are marketed.
They normally have a nominal content of biological activity, with
speciﬁcations around this for acceptance. For example, a product
may have a nominal potency of 100 units/ml with acceptance limits
of 80e125% around this. Thus, they do not have a single deﬁned
value of biological activity. In the example quoted, the actual bio-
logical potency could be any value between 80 and 125 units/ml
and there is no way of knowing what this value is. This implies that
they cannot be used to calibrate assays. Reference standards, such
as WHO international standards have a deﬁned unitage and so they
are ideally suited for the calibration of assays.
WHO international standards/reference reagents are not clinical
products, even though the active substance in themmay be derived
from a product that was produced at clinical grade. They do not
have any history of clinical use and are often formulated using
excipients which are very different to those used in clinical prod-
ucts. They are usually lyophilized during their preparation, which
means they have been subjected to additional procedures than
those used for clinical products. Therefore, these reagents are
clearly inappropriate for use as comparators for biosimilar product
development and should not be used for such purposes. Reference
products are essential for demonstrating the similarity of the SBP.
5. Conclusions
For the development of SBPs, the use of a reference product for
the comparability studies is essential. There has been somediscussion on providing ‘standard’ reference products which can be
used for in the development of SBPs, but this is not feasible as the
reference product must be a commercial clinical product with an
established clinical record. Reference products cannot be used as
‘standards’ for calibration of assays.
In contrast, WHO international standards and reference
reagents are used for calibrating procedures, particularly bioassays.
They are not clinical products, and therefore cannot be used as
comparators during SBP development.
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